Company intelligence / Profile preview
PulmoSIM Therapeutics
United Statespulmosimtx.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Developing PT001, granted FDA Orphan Drug Designation for PAH; initiating clinical development via partnerships with respiratory hospitals. No clinical results reported yet.
- Therapeutic areas
- CardiovascularPulmonology
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Strategic partnerships with top respiratory hospitals for PT001 clinical development
Beyond the preview
Go deeper on PulmoSIM Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PulmoSIM Therapeutics.